Compare FMNB & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | ANNX |
|---|---|---|
| Founded | 1887 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.4M | 812.7M |
| IPO Year | 2010 | 2020 |
| Metric | FMNB | ANNX |
|---|---|---|
| Price | $14.82 | $5.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $15.00 | ★ $16.50 |
| AVG Volume (30 Days) | 532.5K | ★ 4.4M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | ★ 18.85 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $279,922,000.00 | N/A |
| Revenue This Year | $52.63 | N/A |
| Revenue Next Year | $8.28 | $16,320.74 |
| P/E Ratio | $41.67 | ★ N/A |
| Revenue Growth | ★ 3.89 | N/A |
| 52 Week Low | $12.23 | $2.03 |
| 52 Week High | $15.50 | $7.18 |
| Indicator | FMNB | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | N/A |
| Support Level | $13.75 | N/A |
| Resistance Level | $14.97 | N/A |
| Average True Range (ATR) | 0.26 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 74.75 | 0.00 |
Farmers National Banc Corp is a financial holding company based in the U.S. Along with its subsidiaries, it operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The group offers a full range of commercial and retail banking services, including checking accounts, savings accounts, time deposit accounts, commercial, mortgage, and installment loans, safe deposit boxes, ATMs, internet banking, and other banking services. Additionally, it offers personal and corporate trust services in the areas of estate settlement, trust administration, employee benefit plans, and retirement services; insurance products, and other financial products and services. The group's reportable segments are Bank, which generates the maximum revenue, and Trust.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.